Tuftsin–phosphorylcholine (TPC) equally effective to methylprednisolone in ameliorating lupus nephritis in a mice model
- 26 April 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 193 (2) , 160-166
Abstract
BACKGROUND: The role of helminth treatment in autoimmune diseases is constantly growing. Systemic lupus erythematosus (SLE) is a multi‐system autoimmune disease with challenging treatment options. Tuftsin phosphorylcholine (TPC) is a novel helminth‐based compound that modulates the host immune network. OBJECTIVES: This study was conducted to evaluate the potential value of TPC in ameliorating lupus nephritis in a murine model and specifically to compare the efficacy of TPC to the existing first‐line therapy for SLE: corticosteroids (methylprednisolone). STUDY DESIGN AND METHODS: Lupus‐prone NZBxW/F1mice were treated with TPC (5 µg/mouse), methylprednisolone (MP; 5mg/body weight) or PBS (control) three times per week once glomerulonephritis, defined as proteinuria of grade > 100 mg/dL, was established. Levels of anti‐dsDNA autoantibodies were evaluated by ELISA, splenic cytokines were measured in‐vitro, and the kidney microscopy was analyzed following staining. RESULTS: TPC and MP treatments significantly improved lupus nephritis and prolonged survival in NZBxW/F1 mice. TPC‐treated mice showed a significantly decreased level of proteinuria (p<0.001) and anti‐dsDNA antibodies (p<0.001) as compared to PBS‐treated mice. Moreover, TPC and MP inhibited the production of the pro‐inflammatory cytokines IFN‐γ, IL‐1β, and IL‐6 (p<0.001) and enhanced expression of the anti‐inflammatory cytokine IL‐10 (p<0.001). Finally, microscopy analysis of the kidneys demonstrated that TPC‐treated mice maintained normal structure equally to MP‐treated mice. CONCLUSIONS: This data indicates that the small molecule named TPC hinders lupus development in genetically lupus‐prone mice equally as methylprednisolone in most of the cases. Hence, TCP may be employed as a therapeutic potential for lupus nephritis.Keywords
Funding Information
- Felix and Ruth Zandman Foundation
This publication has 40 references indexed in Scilit:
- Systemic lupus erythematosusThe Lancet, 2014
- Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatmentThe Lancet, 2013
- Systemic Lupus ErythematosusNew England Journal of Medicine, 2011
- Oxidized Phospholipid Inhibition of Toll-like Receptor (TLR) Signaling Is Restricted to TLR2 and TLR4Journal of Biological Chemistry, 2008
- Trichuris suis therapy for active ulcerative colitis: A randomized controlled trialGastroenterology, 2005
- Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosusInternational Immunology, 2002
- Tuftsin: On the 30-year anniversary of Victor Najjar’s discoveryPeptides, 1999
- Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: A longitudinal data analysisThe American Journal of Medicine, 1994
- Hay fever, hygiene, and household size.BMJ, 1989
- Glucocorticoids Administered In Vivo Inhibit Human Suppressor T Lymphocyte Function and Diminish B Lymphocyte Responsiveness in In Vitro Immunoglobulin SynthesisJournal of Clinical Investigation, 1978